Clinical trial
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
NCT00084487
Study timeline
Study start (unknown)2004-04-01Date precision: month
Registry last updated2014-05-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Extensive Stage Small Cell Lung Cancerunresolved
Limited Stage Small Cell Lung Cancerunresolved
Recurrent Small Cell Lung Cancerunresolved
Interventions
becatecarinDRUG
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00084487 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.